Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate stabilization
Airway breathing circulation priorities
Position of comfort
Upright
Avoid supine if severe dyspnea
Oxygenation targets
SpO2 94 to 98 percent for most
SpO2 88 to 92 percent if chronic hypercapnia risk
Monitoring
Continuous pulse oximetry
Cardiac monitor for severe symptoms or high dose beta agonist
Escalation triggers
If silent chest or minimal air movement, resuscitation bay
If altered mental status, resuscitation bay
If SpO2 < 90 percent despite oxygen, resuscitation bay
If impending exhaustion, early airway plan
Time zero treatments
Inhaled short acting beta agonist
Metered dose inhaler with spacer preferred if feasible
Continuous nebulization for severe exacerbation
Inhaled anticholinergic
Add for moderate to severe exacerbation
Systemic corticosteroid
Early administration within first hour when moderate to severe
Reassessment interval
Every 15 to 30 minutes until improving
After each treatment cycle for disposition decisions
Severity stratification
Bedside severity categories
Mild
Speaks full sentences
Minimal accessory muscle use
PEF or FEV1 at least 70 percent predicted or personal best
Moderate
Speaks in phrases
Accessory muscle use
PEF or FEV1 40 to 69 percent predicted or personal best
Severe
Speaks in words
Marked work of breathing
PEF or FEV1 < 40 percent predicted or personal best
Life threatening
Drowsiness confusion
Silent chest
Cyanosis
Bradycardia or hypotension
PEF < 25 percent predicted or personal best
Objective response markers
Dyspnea trend
Speech improvement
Accessory muscle reduction
Airflow trend
PEF improvement at least 60 to 70 percent predicted or personal best
Reduced wheeze intensity with improved air entry
Gas exchange trend
SpO2 improvement to target range
Rising PaCO2 as a fatigue marker in severe disease
Key decision points
Alternative diagnosis triggers
If unilateral absent breath sounds, pneumothorax consideration
If fever focal crackles, pneumonia consideration
If pleuritic chest pain hypoxemia, pulmonary embolism consideration
If stridor, upper airway obstruction consideration
Ventilatory failure risk
If PaCO2 normal or elevated in severe attack, fatigue concern
If worsening acidosis, imminent failure concern
If decreasing respiratory rate with persistent distress, exhaustion concern
Consultation triggers
If life threatening features, critical care
If need for noninvasive ventilation or intubation, anesthesia or ICU
If refractory to ED maximal bronchodilators, ICU
History
Presenting features and trajectory
Symptom pattern and timing
Onset time
Minutes to hours
Days with progressive worsening
Peak severity time
Current worst point
Nocturnal symptoms
Prior similar episodes
Typical response to inhaler
Prior intubation or ICU
Triggers and exposures
Viral upper respiratory symptoms
Fever
Sick contacts
Allergen exposure
Pets
Dust mites
Irritants
Smoke vaping
Occupational fumes
Exercise cold air
Recent exertion
Cold exposure
Medication triggers
Nonselective beta blockers
NSAID sensitivity history
Baseline asthma control and risk
Baseline control markers
Daytime symptoms frequency
More than twice weekly
Daily symptoms
Night waking frequency
Any night waking
Frequent night waking
Activity limitation
School work exercise limitation
Missed school work days
Exacerbation risk markers
Prior ED visit hospitalization
Past 12 months
Multiple ED visits
Prior intubation or ICU
Any history
Recent history
Overuse of short acting beta agonist
Multiple canisters per month
Frequent rescue use
Underuse of controller therapy
No inhaled corticosteroid
Poor adherence
Medications and comorbidities
Current therapies
Rescue inhaler details
Last dose time
Number of puffs in last 24 hours
Controller therapy
Inhaled corticosteroid dose
ICS LABA use
Recent systemic steroid
Within past 30 days
Dose and duration
Comorbid conditions
Anaphylaxis allergy history
Food venom medication allergy
Urticaria angioedema symptoms
COPD overlap or smoking history
Long smoking history
Chronic sputum
Cardiac disease
Heart failure history
Arrhythmia history
Gastroesophageal reflux
Heartburn regurgitation
Chronic cough pattern
Mental health and anxiety
Panic symptoms
Hyperventilation episodes
Physical Exam
Respiratory assessment
Work of breathing
Accessory muscle use
Intercostal retractions
Suprasternal retractions in pediatrics
Speech limitation
Full sentences
Words only
Respiratory rate
Age adjusted tachypnea
Declining rate with exhaustion concern
Auscultation
Wheeze distribution
Diffuse expiratory
Inspiratory component in severe
Air entry
Good air movement
Reduced air movement
Silent chest
Focal findings
Localized crackles
Unilateral reduction
Oxygenation and perfusion
SpO2 on room air and oxygen
< 90 percent severe marker
Response to oxygen
Heart rate
Tachycardia expected with distress or beta agonist
Bradycardia late warning
Blood pressure
Hypertension from catecholamine response
Hypotension severe marker
General and high risk signs
Mental status
Agitation anxiety
Early hypoxemia sign
Hyperventilation pattern
Drowsiness confusion
Hypercapnia marker
Impending failure marker
Ability to lie flat
Tripod posture
Orthopnea differential consideration
Hydration and fatigue
Dry mucous membranes
Exhaustion posture
PITFALLS
False reassurance patterns
Reduced wheeze with worsening air entry
Silent chest as critical sign
Minimal chest movement as critical sign
Normal initial SpO2 in early bronchospasm
Rapid deterioration risk
Continuous monitoring need
Differential Diagnosis
Life threatening mimics
Alternative diagnoses requiring exclusion
Anaphylaxis
Hypotension
Urticaria angioedema
Upper airway obstruction
Stridor
Foreign body aspiration
Pneumothorax
Sudden pleuritic pain
Unilateral absent breath sounds
Pulmonary embolism
Pleuritic pain
Risk factors and hypoxemia
Heart failure pulmonary edema
Crackles
Peripheral edema
Common competing conditions
Lower respiratory infections
Pneumonia
Fever focal crackles
Pleuritic pain
Acute bronchitis
Cough predominant
Minimal airflow limitation
COPD exacerbation
Older age smoking history
Chronic sputum
Vocal cord dysfunction
Inspiratory wheeze or stridor
Poor response to bronchodilator
Anxiety hyperventilation syndrome
Paresthesias
Normal lung exam between episodes
Coding anchors
ICD 10 compatible terms
Asthma with acute exacerbation
J45.901 unspecified asthma with acute exacerbation
J45.21 mild intermittent asthma with acute exacerbation
J45.31 mild persistent asthma with acute exacerbation
J45.41 moderate persistent asthma with acute exacerbation
J45.51 severe persistent asthma with acute exacerbation
Status asthmaticus
J45.902 unspecified asthma with status asthmaticus
Laboratory Tests
Core labs by indication
Targeted labs for severe or atypical presentations
Arterial or venous blood gas for ventilatory failure concern
Rising PaCO2 marker
Normalization or elevation in severe attack as fatigue marker
Worsening acidosis as imminent failure marker
PaO2 assessment if severe hypoxemia
PaO2 in mmHg
A a gradient interpretation when needed
Electrolytes for high dose beta agonist
Potassium
Hypokalemia risk from beta agonist shift
Repletion planning when symptomatic or significant
Glucose
Hyperglycemia risk from beta agonist and steroids
Diabetes management consideration
CBC for infection concern
Leukocytosis interpretation caution
Steroid related demargination
Stress leukocytosis
Point of care testing
ED rapid tests when clinically indicated
Viral testing based on local policy
Influenza or SARS CoV 2 when it changes management
Outbreak context
Lactate for shock concern
Alternative causes of elevated lactate
Beta agonist associated lactate elevation
Sepsis physiology differentiation
PITFALLS
Lab limitations
ABG or VBG not routine in mild to moderate
Clinical response as primary guide
Over testing risk
Leukocytosis not equal bacterial infection
Clinical and imaging correlation
Antibiotic stewardship
Diagnostic Tests
Scoring Systems
Structured severity tools
Peak expiratory flow based stratification
PEF percent predicted or personal best
At least 70 percent mild
40 to 69 percent moderate
< 40 percent severe
< 25 percent life threatening
Response categories
PEF at least 60 to 70 percent after treatment supports discharge consideration
PEF < 40 percent after treatment supports admission consideration
Pediatric asthma scores
PRAM Pediatric Respiratory Assessment Measure
Suprasternal indrawing
Scalene muscle use
Air entry
Wheeze
Oxygen saturation
Use cases
Serial reassessment for response
Communication between teams
MRI
Role of MRI
Not routine for acute exacerbation
Time constraints
Limited acute utility
Alternative diagnoses evaluation
If mediastinal mass suspicion
If complex congenital airway considerations in pediatrics
CT
Role of CT
Not routine for acute exacerbation
Radiation and time
Reserve for alternative diagnosis
Indications for CT chest consideration
If suspected pulmonary embolism
Persistent hypoxemia disproportionate to wheeze
Pleuritic pain and risk factors
If suspected complications
Pneumomediastinum with chest pain and subcutaneous emphysema
Atypical focal findings with non diagnostic radiograph
Ultrasound
POCUS adjuncts
Lung ultrasound for alternative diagnoses
Pneumothorax evaluation
Absent lung sliding
Lung point
Pulmonary edema evaluation
B lines pattern
Pleural effusions
Cardiac ultrasound when indicated
Right heart strain with PE concern
Global function in shock
Chest radiograph role
Indications
First presentation or uncertain diagnosis
Fever focal findings
Suspected pneumothorax pneumomediastinum
Poor response to therapy
Typical findings
Hyperinflation
Peribronchial thickening
Normal radiograph common
Disposition
Admission and ICU criteria
Level of care decisions
ICU indications
Life threatening features
Silent chest
Altered mental status
Persistent hypoxemia
SpO2 < 90 percent despite oxygen
PaO2 persistently low in mmHg
Hypercapnia or acidosis
Rising PaCO2
Worsening pH
Need for ventilatory support
Noninvasive ventilation
Intubation
Ward admission indications
Persistent moderate to severe symptoms after ED therapy
Need for frequent bronchodilator
PEF < 40 to 50 percent predicted or personal best after treatment
Social or access barriers
Poor follow up reliability
Inability to obtain medications
ED discharge criteria
Discharge readiness
Clinical stability
Minimal work of breathing
Speaks in full sentences or age appropriate baseline
Objective measures
PEF at least 60 to 70 percent predicted or personal best
SpO2 at target on room air or baseline oxygen
Treatment spacing
Short acting beta agonist no more frequent than every 4 hours
Sustained response at least 60 minutes after last bronchodilator
Plan completeness
Systemic steroid course started
Controller plan provided
Follow up arranged
Transfer considerations
Interfacility transfer triggers
No ICU capability locally with severe attack
Need for continuous nebulization with close monitoring beyond local capacity
Pediatric critical care requirement
Treatment
Bronchodilators and steroids
Inhaled short acting beta agonist
Albuterol salbutamol dosing
Adults MDI spacer
4 to 8 puffs every 20 minutes for 1 hour then reassess
4 to 8 puffs every 1 to 4 hours as needed
Adults nebulized
2.5 to 5 mg every 20 minutes for 3 doses
Continuous 10 to 15 mg per hour for severe
Pediatrics nebulized
0.15 mg per kg per dose
Minimum 2.5 mg per dose
Maximum 5 mg per dose
Every 20 minutes for 3 doses then reassess
Monitoring with high dose therapy
Tachycardia tremor
Hypokalemia surveillance
Levalbuterol option
Similar efficacy
Consider if significant tachyarrhythmia concern
Inhaled anticholinergic
Ipratropium dosing
Adults nebulized
0.5 mg every 20 minutes for 3 doses
Pediatrics nebulized
0.25 to 0.5 mg every 20 minutes for 3 doses
Combination therapy
Add to SABA for moderate to severe in first hour
Reduced hospitalization in severe presentations
Systemic corticosteroid
Prednisone or prednisolone oral
Adults
40 to 60 mg daily for 5 to 7 days
No taper for short course in most
Pediatrics
1 to 2 mg per kg per day
Maximum 60 mg per day
3 to 5 days typical
Methylprednisolone IV
Indications
Unable to tolerate oral
Severe exacerbation with vomiting or impending failure
Adults dosing
60 to 125 mg IV initial
Pediatrics dosing
1 mg per kg IV
Maximum 60 mg per dose
Adjunct therapies for severe or refractory
Magnesium sulfate IV
Indications
Severe exacerbation with poor response to initial bronchodilators
PEF or FEV1 < 25 to 30 percent predicted or personal best
Adults dosing
2 g IV over 20 minutes
Hypotension monitoring
Pediatrics dosing
25 to 50 mg per kg IV over 20 to 30 minutes
Maximum 2 g
Evidence
Reduced hospitalization in severe exacerbations in multiple trials and meta analyses
Epinephrine
Indications
Anaphylaxis with bronchospasm
Life threatening asthma with poor inhaled delivery and impending arrest as rescue consideration
IM dosing for anaphylaxis
Adults
0.5 mg IM of 1 mg per mL
Pediatrics
0.01 mg per kg IM of 1 mg per mL
Maximum 0.3 mg per dose prepubertal
Maximum 0.5 mg per dose adolescent
Nebulized epinephrine
Role limited
Consider primarily for upper airway edema not typical asthma
Noninvasive ventilation
Indications
Severe work of breathing with hypercapnia risk
Cooperative patient without immediate intubation need
Contraindications
Altered mental status inability to protect airway
Hemodynamic instability
Monitoring needs
Continuous monitoring
Early reassessment for failure
Ketamine
Role
Induction agent with bronchodilatory properties during intubation
Analgosedation option in ventilated severe asthma
Dosing examples
RSI induction 1 to 2 mg per kg IV
Analgosedation infusion 0.5 to 2 mg per kg per hour titrated
Heliox
Consideration
Severe airflow obstruction with poor aerosol delivery
Availability dependent
Limitations
Requires high helium fraction
Reduced effectiveness if high oxygen requirement
Therapies generally not recommended
Antibiotics
Not routine
Reserve for clear bacterial infection evidence
Stewardship emphasis
Mucolytics
Not recommended in acute asthma
Sedatives without airway plan
Avoid due to hypoventilation risk
Airway and ventilation
Intubation indications
Respiratory arrest or peri arrest
Altered mental status with inability to protect airway
Refractory hypoxemia or hypercapnia with acidosis
Exhaustion with impending failure
Ventilation strategy for intubated severe asthma
Dynamic hyperinflation mitigation
Low respiratory rate
Prolonged expiratory time
Permissive hypercapnia with pH target individualized
Barotrauma monitoring
High peak pressures
Pneumothorax surveillance
Auto PEEP recognition
Hypotension after ventilation initiation
Ventilator flow not returning to baseline
Evidence and guideline anchors
Inhaled SABA and systemic corticosteroid as first line standard of care
Broad guideline consensus
Early steroid reduces relapse and admission risk
Add ipratropium for moderate to severe in ED
Evidence supports reduced admissions in severe presentations
IV magnesium for severe refractory cases
Evidence supports reduced hospital admission in severe attacks
Special Populations
Pregnancy
Pregnancy specific considerations
Maternal oxygenation priority
SpO2 target at least 95 percent commonly used to support fetal oxygenation
Early escalation when hypoxemic
Medication safety
Inhaled SABA preferred rescue
Inhaled corticosteroid continuation
Systemic corticosteroid when indicated
Obstetric collaboration triggers
Severe exacerbation
Reduced fetal movement or bleeding
Differential emphasis
Pulmonary embolism risk increased in pregnancy
Preeclampsia pulmonary edema consideration
Geriatric
Older adult considerations
Cardiac comorbidity and beta agonist effects
Tachyarrhythmia risk
Ischemia risk in coronary disease
COPD overlap
Baseline hypercapnia possibility
Oxygen targets individualized
Medication interactions
Beta blocker use
Polypharmacy review
Frailty and disposition
Lower threshold for observation or admission
Home support assessment
Pediatrics
Pediatric specific considerations
Weight based dosing
SABA nebulized 0.15 mg per kg per dose
Magnesium 25 to 50 mg per kg IV
Clinical markers
Suprasternal retractions
Poor feeding or lethargy
Delivery method
MDI spacer effectiveness
Mask fit importance
Admission threshold lower in young children
History of severe attack
Persistent need for frequent bronchodilator
Background
Epidemiology
Burden and patterns
Common ED presentation across age groups
Seasonal viral peaks
Allergen related peaks
Exacerbation relapse risk after ED visit
Higher with prior severe history
Higher with poor controller adherence
Mortality concentrated in high risk groups
Prior ICU or intubation history
High SABA use and low ICS use
Pathophysiology
Core mechanisms
Bronchial smooth muscle constriction
Rapid onset component
Reversibility with bronchodilator
Airway inflammation and edema
Slower response component
Steroid responsive component
Mucus plugging
Ventilation perfusion mismatch
Atelectasis risk
Dynamic hyperinflation in severe attack
Increased work of breathing
Auto PEEP and hemodynamic compromise
Therapeutic Considerations
Rationale for first line therapies
SABA mechanism
Beta 2 receptor mediated bronchodilation
Rapid symptom relief
Anticholinergic add on
Reduced vagal bronchoconstriction
Additive bronchodilation with SABA
Systemic corticosteroid
Reduced airway inflammation
Reduced relapse after discharge
Magnesium sulfate
Smooth muscle relaxation
Greatest benefit in severe obstruction
Controller therapy after exacerbation
Inhaled corticosteroid foundation
Reduced future exacerbations
Reduced need for systemic steroids
Follow up and action plan reduces recurrence
Trigger avoidance strategies
Inhaler technique correction
Patient Discharge Instructions
copy discharge instructions
Discharge plan
Medications
Rescue inhaler use
2 to 4 puffs every 4 hours as needed
Spacer use if available
Oral steroid course completion
Take daily until finished
Take with food if stomach upset
Controller therapy
Continue daily inhaled steroid if prescribed
Start inhaled steroid if newly prescribed
Trigger control
Avoid smoke vaping exposure
Avoid known allergens when possible
Viral infection precautions
Follow up timing
Primary care or asthma clinic within 1 to 3 days for moderate to severe ED visit
Within 7 days for mild ED visit
Return immediately for
Trouble speaking due to breathing
Lips or face turning blue or gray
Severe chest tightness not improving after rescue inhaler
Need for rescue inhaler more often than every 4 hours
Fainting confusion extreme sleepiness
Chest pain or one sided decreased breath sounds
Device technique
Spacer technique review
Nebulizer cleaning instructions if used
Written asthma action plan
Green yellow red zone guidance
Peak flow use if available
References
Clinical guidelines and evidence sources
Guideline sources
Global Initiative for Asthma
GINA strategy for asthma management and prevention
ED acute exacerbation principles and discharge planning
NHLBI NAEPP focused updates
Controller strategies and risk reduction concepts
Stepwise therapy framework
British Thoracic Society SIGN guideline
Acute asthma assessment and management framework
Severity features and escalation triggers
Evidence base for key ED therapies
Ipratropium plus SABA in acute severe asthma
Reduced hospitalization in severe attacks in multiple trials
Greatest benefit in first hour treatment bundles
Early systemic corticosteroid in ED
Reduced relapse and admission in meta analyses
Benefit greatest when given early
IV magnesium sulfate for severe exacerbation
Reduced hospitalization in severe exacerbations in meta analyses
Benefit most consistent in severe obstruction
Ventilation strategies for status asthmaticus
Low minute ventilation approach for hyperinflation avoidance
Barotrauma risk mitigation principles
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.